New hope for myelofibrosis patients with severe anemia

NCT ID NCT04455841

Ongoing Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 01, 2026 · Updated 19 times

Summary

This early-stage study tests an experimental drug called INCB000928, given alone or with a standard medicine (ruxolitinib), for people with myelofibrosis who have low red blood cells (anemia) and need frequent blood transfusions. The goal is to see if the drug is safe and can raise hemoglobin levels or reduce transfusion needs. About 84 participants will take part in this open-label study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Azienda Ospedaliera Papa Giovanni Xxiii

Bergamo, 24127, Italy
Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano

Orbassano, 10043, Italy
Azienda Ospedaliero-Universitaria Careggi (Aouc)

Florence, 50134, Italy
Centre Hospitalier D'Angers

Angers, 49033, France
Chiba Cancer Center

Chiba, 260-8717, Japan
City of Hope National Medical Center

Duarte, California, 91010, United States
City of Hope Orange County

Irvine, California, 92618, United States
Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo

Pavia, 27100, Italy
Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy

Durham, North Carolina, 27705, United States
Emory University - Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Emory University-Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Gifu Municipal Hospital

Gifu, 500-8513, Japan
Hospital Saint Louis

Paris, 75010, France
Institut Paoli Calmettes

Marseille, 13273, France
Kansai Medical University Hospital

Hirakata, 573-1191, Japan
Kumamoto Shinto General Hospital

Kumamoto, 862-8655, Japan
Lincoln County Hospital

Lincoln, LN2 5QY, United Kingdom
McGill University Jewish General Hospital

Montreal, Quebec, H3T1E2, Canada
Md Anderson Cancer Center

Houston, Texas, 77030, United States
Osaka International Cancer Institute

Osaka, 541-8567, Japan
Ospedale Santa Maria Della Misericordia Perugia

Perugia, 06124, Italy
Prebys Cancer Center

San Diego, California, 92103, United States
Princess Margaret Cancer Center

Toronto, Ontario, M5G 2M9, Canada
Royal Cornwall Hospital Truro Sunrise Centre

Truro, TR1 3LJ, United Kingdom
S Orsolas University Hospital Seragnoli Institute of Hematology

Bologna, 40138, Italy
Stanford Cancer Center

Palo Alto, California, 94304, United States
Start Midwest

Grand Rapids, Michigan, 49546, United States
Tokyo Medical and Dental University Hospital

Bunkyō City, 113-8519, Japan
United Lincolnshire Hospitals

Boston, PE21 9QS, United Kingdom
University Hospital of Wales

Cardiff, WLS, CF14 4XW, United Kingdom
Usc Norris Comprehensive Cancer Center

Los Angeles, California, 90089, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Weill Cornell Medical Centers

New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.

ANEMIA POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS POST POLYCYTHEMIA VERA MYELOFIBROSIS POST-POLYCYTHEMIA VERA MYELOFIBROSIS